Full Text (PDF)
Case Report

Neonatal Severe Hyperparathyroidism: A Case Report

Manikandan U., Meenakshi Sundari S., Karuppasamy N., Srinivasakumar R., Aravindan C., Selvakumar G.

Author Information

Licence:

Attribution-Non-commercial 4.0 International (CC BY-NC 4.0)

This license enables reusers to distribute, remix, adapt, and build upon the material in any medium or format for noncommercial purposes only, and only so long as attribution is given to the creator.


New Indian Journal of Surgery 14(4):p 193-197, October-December 2023. | DOI: https://doi.org/10.21088/nijs.0976.4747.14423.4

How Cite This Article:

Manikandan U., Meenakshi Sundari S., Karuppasamy N., et al./Neonatal Severe Hyperparathyroidism: A Case Report/New Indian J Surg. 2023; 14(3):193–197.

Timeline

Received : July 27, 2023         Accepted : September 01, 2023          Published : December 25, 2023

Abstract

Background: Neonatal severe hyperparathyroidism is an extremely rare condition that presents in the first few months of life. Recognition at the early stage followed by prompt surgical intervention are of vital importance for survival. Hypotonia, respiratory distress, lethargy and delay in growth and development occur in association with the elevated serum parathormone levels and hypercalcemia. Definitive therapy involves total parathyroidectomy. Case Description: We are presenting a case with Neonatal severe hyperparathyroidism, who underwent total parathyroidectomy. The patient had been followed up with medical therapy until. Parathormone levels rapidly declined following total parathyroidectomy and the patient was discharged with full recovery. Literature Review: Sestamibi scintigraphy might fail to show an ectopic parathyroid gland. In such conditions, on table confirmation of parathyroid glands by frozen section and Intraoperative parathormone monitoring is vital at this point. Persistently elevated parathormone levels might suggest a remnant parathyroid tissue at the surgical site or an ectopic parathyroid gland that should be excised. Clinical Relavance: Neonatal severe hyperparathyroidism is a life-threatening disease. In the present case surgery performed at the early is life-saving due to the failure of medical therapy to control the disease.


References

  • 1.   Anthony W. Gannon, Heather M. Monk, Michael A. Levine, Cinacalcet monotherapy in neonatal severe hyperparathyroidism: a case study and review, J. Clin. Endocrinol. Metab. 99 (January (1)) (2014) 7–11, http://dx.doi. org/10.1210/jc.2013- 2834.
  • 2.   R.A. Agha, M.R. Borrelli, R. Farwana, K. Koshy, A. Fowler, D.P. Orgill, For the SCARE Group, The SCARE 2018 statement: updating consensus surgical CAse REport (SCARE) guidelines, Int. J. Surg. 60 (2018) 132–136.
  • 3.   J. Tfelt-Hansen, E.M. Brown, The calciumsensing receptor in normal physiology and pathophysiology: a review, Crit. Rev. Clin. Lab. Sci. 42 (2005) 35–70.
  • 4.   G.N. Hendy, David E.C. Cole, Genetic defects associated with familial and sporadic hyperparathyroidism, Front. Horm. Res. 41 (2013) 149–165, http://dx.doi.org/10.1159/000345675, Epub 2013 Mar 19.
  • 5.   G.N. Hendy, L. D’Souza-Li, B. Yang, L. Canaff, D.E. Cole, Mutations of the calcium sensing receptor (CASR) in familial hypocalciuric hypercalcemia, neonatal severe hyperparathyroidism, and autosomal dominant hypocalcemia, Hum. Mutat. 16 (2000) 281–296.
  • 6.   Todd M. Brickman, Matthew W. Stark, Anita Jeyakumar, Unusual case of neonatal hypercalcemia, Int. J. Pediatr. Otorhinolaryngol. 79 (5) (2015) 758–759, http://dx.doi.org/10.1016/j. ijporl.2015.02.029.
  • 7.   J.C. Pallais, E.H. Kemp, C. Bergwitz, L. Kantham, D.M. Slovik, A.P. Weetman, E.M. Brown, Autoimmune hypocalciuric hypercalcemia unresponsive to glucocorticoid therapy in a patient with blocking autoantibodies against the calciumsensing receptor, J. Clin. Endocrinol. Metab. 96 (2011) 672–680.
  • 8.   S.J. Marx, D.M. Lourenc¸ o Jr., Familial hyperparathyroidism – disorders of growth and secretion in hormone-secretory tissue, Horm. Metab. Res. 49 (November (11)) (2017) 805–815, http://dx.doi.org/10.1055/s-0043-120670, Epub 2017 Nov 14.
  • 9.   S. Al-Shanafey, R. Al-Hosaini, A. Al-Ashwal, A. AlRabeeah, Surgical management of severe neonatal hyperparathyroidism: one center’s experience, J. Pediatr. Surg. 45 (April (4))(2010) 714–717, http:// dx.doi.org/ 10.1016/j.jpedsurg.2009.08.005.
  • 10.   N. Ahmed, Neonatal severe hyperparathyroidism secondary to an novel homozygous CASR gene mutation, Clin. Cases Miner. Bone Metab. 14 (3) (2017) 354–358.

Data Sharing Statement

There are no additional data available. All raw data and code are available upon request.

Funding

This research received no funding.

Author Contributions

All authors contributed significantly to the work and approve its publication.

Ethics Declaration

This article does not involve any human or animal subjects, and therefore does not require ethics approval.

Acknowledgements

We would like to express our gratitude to the patients, their families, and all those who have contributed to this study.

Conflicts of Interest

No conflicts of interest in this work.


About this article


Cite this article

Manikandan U., Meenakshi Sundari S., Karuppasamy N., et al./Neonatal Severe Hyperparathyroidism: A Case Report/New Indian J Surg. 2023; 14(3):193–197.


Licence:

Attribution-Non-commercial 4.0 International (CC BY-NC 4.0)

This license enables reusers to distribute, remix, adapt, and build upon the material in any medium or format for noncommercial purposes only, and only so long as attribution is given to the creator.


Received Accepted Published
July 27, 2023 September 01, 2023 December 25, 2023

DOI: https://doi.org/10.21088/nijs.0976.4747.14423.4

Keywords

Severe HyperparathyroidismHypercalcemiaCinacalcetSestamibi scintigraphyCaSR Gene

Article Level Metrics

Last Updated

Sunday 22 November 2026, 21:35:17 (IST)


9574

Accesses

10
879
00

Citations


NA
NA
NA

Download citation


Article Keywords


Keyword Highlighting

Highlight selected keywords in the article text.


Timeline


Received July 27, 2023
Accepted September 01, 2023
Published December 25, 2023

licence


Attribution-Non-commercial 4.0 International (CC BY-NC 4.0)

This license enables reusers to distribute, remix, adapt, and build upon the material in any medium or format for noncommercial purposes only, and only so long as attribution is given to the creator.


Access this article



Share